[{"id":"f5ce8c06-3250-40ff-b25a-dd3430d92b46","acronym":"","url":"https://clinicaltrials.gov/study/NCT07078604","created_at":"2025-07-26T13:31:46.938Z","updated_at":"2025-07-26T13:31:46.938Z","phase":"Phase 2","brief_title":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT07078604","lead_sponsor":"University of Washington","biomarkers":" ENG","pipe":"","alterations":" ","tags":["ENG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • Halaven (eribulin mesylate) • pegylated liposomal doxorubicin • daunorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • EP-101 STEMVAC • Leukine (sargramostim)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/01/2025","start_date":" 12/01/2025","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2025-07-22"},{"id":"8ba9e8f3-0202-4655-a1f4-6afdb8352cd1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05455658","created_at":"2022-07-13T12:56:22.409Z","updated_at":"2024-07-02T16:35:05.151Z","phase":"Phase 2","brief_title":"STEMVAC in Patients With Early Stage Triple Negative Breast Cancer","source_id_and_acronym":"NCT05455658","lead_sponsor":"University of Washington","biomarkers":" HER-2 • ER • PGR • IFNG","pipe":" | ","alterations":" HER-2 negative • HER-2 expression • PGR expression","tags":["HER-2 • ER • PGR • IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EP-101 STEMVAC • Leukine (sargramostim)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 11/17/2022","start_date":" 11/17/2022","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-08"},{"id":"7cc5ae09-064d-45f0-a256-7f1ecb9e9888","acronym":"","url":"https://clinicaltrials.gov/study/NCT05242965","created_at":"2022-02-16T15:53:31.281Z","updated_at":"2024-07-02T16:35:11.872Z","phase":"Phase 2","brief_title":"A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05242965","lead_sponsor":"University of Washington","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EP-101 STEMVAC • Leukine (sargramostim)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/24/2023","start_date":" 03/24/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-04-02"},{"id":"4a8336ce-ca25-401e-8327-5f31b0110474","acronym":"","url":"https://clinicaltrials.gov/study/NCT02157051","created_at":"2021-01-18T10:01:56.771Z","updated_at":"2024-07-02T16:35:19.570Z","phase":"Phase 1","brief_title":"Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer","source_id_and_acronym":"NCT02157051","lead_sponsor":"University of Washington","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EP-101 STEMVAC"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 11/25/2022","primary_completion_date":" 11/25/2022","study_txt":" Completion: 02/10/2027","study_completion_date":" 02/10/2027","last_update_posted":"2024-02-13"}]